Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...

In 2021, Sly, biochemistry professor Harry Brumer, and a group of other researchers at the UBC developed GlycoCage, a ...

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable clinical and endoscopic remission through 92 weeks in adults with moderately to ...

Symptoms of inflammatory bowel disease (IBD) range from diarrhea and abdominal pain to nausea, fever, loss of appetite, fatigue and, at times, rectal bleeding. No single test can confirm IBD, which ...

A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments. The proof-of-concept study introduced a ...

In this Healio video, Edward L. Barnes, MD, MPH, associate professor of medicine, co-director of the Multidisciplinary IBD Center and associate fellowship program director at the University of North ...

Researchers and clinicians have developed major new guidelines for the monitoring of patients with inflammatory bowel disease ...

Coverage for ulcerative colitis specialists and treatment can depend on your specific health insurance plan and whether healthcare professionals are in your network. Planning for the future with a ...